SS-31 (Elamipretide)
FDA ApprovedA mitochondria-targeting peptide that reduces oxidative stress and improves mitochondrial function. FDA approved for Barth syndrome. Researched for heart failure, aging, and energy.
LongevityCardiovascularEnergy & PerformanceMitochondrial Health
Half Life
~2 hours
Time to Results
Weeks to months
Administration
SubQ injection, IV
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyDaily
Cost$$$
🐾 Griffin Says...
FDA approved for Barth syndrome in 2025, making it one of the newest additions to the approved list. The mitochondrial targeting mechanism is unique and fascinating. Strong scientific basis for cardiovascular and aging research.
Benefits
- Mitochondrial function improvement
- Reduced oxidative stress
- Cardiovascular support
- Energy production
- Anti-aging potential
Best For
- Mitochondrial health research
- Cardiovascular research
- Anti-aging
- Energy research
Body Systems
CardiovascularCellularMetabolic
Mechanisms of Action
- Targets cardiolipin in inner mitochondrial membrane
- Reduces reactive oxygen species
- Improves electron transport chain efficiency
- Protects mitochondrial function
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Injection site reactions | Common | Mild |
| Fatigue initially | Uncommon | Mild |
Contraindications
None well established outside of indicated conditions
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator